

29 Jan 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: Merck & Co. tells *Scrip* oncology will remain a key priority; J&J is responsibly cautious on growth; Takeda pays big for HutchMed drug; industry looks at likely US IRA impact; and lecanemab misses out on EU fast-track treatment.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 27 January 2023, including: [*Merck & Co., Inc.*](#) tells *Scrip* oncology will remain a key priority; [*Johnson & Johnson*](#) is responsibly cautious on growth; [*Takeda Pharmaceutical Co. Ltd.*](#) pays big for [*HUTCHMED \(China\) Limited*](#) drug; industry looks at likely US IRA impact; and lecanemab misses out on EU fast-track treatment.

This and all our other podcasts are available on the Pharma Intelligence channel on [*Apple Podcasts*](#), [*Google Podcasts*](#), [*SoundCloud*](#), [*TuneIn*](#) and [*Spotify Podcasts*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[*As Merck Diversifies Beyond Keytruda, It Will Lean On Its Oncology Leadership Position*](#)" - *Scrip*, 19 Jan, 2023.)

(Also see "[*J&J Lays Out 'Responsibly Cautious' Growth Outlook*](#)" - *Scrip*, 24 Jan, 2023.)

(Also see "[*Takeda Pays Big For De-Risked HutchMed CRC Drug*](#)" - *Scrip*, 23 Jan, 2023.)

(Also see "[*Industry Looks At IRA Drawbacks And Silver Linings*](#)" - *Scrip*, 20 Jan, 2023.)

(Also see "[*No Fast Track For Lecanemab In EU Disappoints Eisai*](#)" - *Scrip*, 19 Jan, 2023.)

[Click here to explore this interactive content online](#) 